I don't see it as a big issue for now, do you?
The shouldn't need to dilute for awhile and maybe the shares for management might actually provide some incentive to create more shareholder value.
I haven't heard that before. Riley the best diluter in the business?
How would he approach dilution now? ATM? Or some other mechanism?
25 cents now would represent only 1.25 cents pre-RS.
I wonder if Furbush ever finally gave up on Punit.
Sal--what do you believe will be the trading range for this thing in 2016?
$1.20 to $1.80?
We'll be back on an eventual sector rebound.
Technically, it's also way oversold.
We'll have more news too.
Little downside risk at these levels.
Grateful to see my clarion call out to you answered, Justice!
Many thanks for all of the due diligence you have put into ADXS and ZIOP. It is VERY much appreciated by those who understand biotech. As for the others, well, they have a lot to learn, and it may be painful for them in the short-term.
May you have a blessed Christmas and I wish you and your family all of the best in 2016. Holiday cheers!
ADXS held up relatively well, given all of the market carnage today.
And especially after the huge run-up this week. Very little profit-taking, which is a positive. A new base is firming-up nicely.
We will be near $13 by EOY and possibly $15 by the JPM conference in mid-January.